热门资讯> 正文
Duravyu后期试验的招募更新后，EyePoint崛起
2026-07-31 01:52
- Shares of EyePoint (EYPT) gained on Thursday after the company said that two late-stage trials for its lead asset, Duravyu, completed enrollments ahead of schedule, validating its confidence in the program.
- The global trials named COMO and CAPRI are designed to evaluate the intravitreal insert in both newly diagnosed and previously treated patients with diabetic macular edema, the leading cause of blindness in patients with type 1 and type 2 diabetes.
- Both studies have completed enrollments in only five months, adding more than 480 patients ahead of their topline readouts scheduled for Q4 2027, the company said.
- "DURAVYU's compelling efficacy and safety profile, combined with positive feedback on our trial design from both the FDA and EMA, underscores our confidence in the program as we advance toward topline data in DME anticipated next year,” added CEO Jay Duker.
More on EyePoint Pharmaceuticals
- EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- EyePoint: DURAVYU's Durability Could Drive Significant Upside
- EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
- EyePoint to pay $4.6M to settle with DoJ over kickback claims
- EyePoint targets wet AMD Phase III top line data mid-year while projecting cash runway into Q4 2027
推荐文章
港股周报 | 黄金股狂飙！灵宝黄金周升24%；段永平“被动减持”泡泡玛特；药明康德升近20%创新高
一周财经日历 | 重磅财报周！腾讯、Lumentum、中芯国际轮番登场！美国7月CPI携零售数据来袭
8月8日外盘头条：伊朗内部辩论霍尔木兹协议措辞 非农爆冷削弱加息预期 SpaceX将自建发电厂保障电力供应
Palantir股价将创下自2024年以来最佳单周表现，该股已不再是AI领域的失意者
7月非农就业数据走弱，支持美联储维持利率不变，但加息选项并未彻底排除
美股前瞻 | 聚焦20：30！市场静候7月非农数据；特朗普政府拟加码布局关键矿产；应用光电计划大规模扩产，光通信盘前集体飙升
港股异动 | 创新药概念再度走强，再鼎新药劲升14%，Q2产品收入环比增长11%；药明生物升逾5%，百济神州升逾3%
港股异动 | AI硬件股多数上涨，建滔积层板、胜宏科技涨逾5%，兆易创新涨逾3%；南方两倍做多海力士跌逾9%
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
